Author of

• 15382

  +

  P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15473

    +

    P3.04-091 - Expression of Cytoplasmic ECT2 as a New Prognostic Marker for Early-Stage Lung Adenocarcinoma (ID 2194)

    09:30 - 09:30  |  Author(s): Z. Kosibaty
    • Abstract
    • Slides

    Background:
    We have examined genetic abnormalities in early-stage lung adenocarcinoma (LAd) using array-comparative genomic hybridization (array-CGH) and found that ECT2 amplification and overexpression can be a new prognostic marker (Cancer Science, 2014). In normal cells, ECT2 is localized in the nucleus, and its function is associated with cytokinesis. In cancer cells, however, ECT2 is thought to exist in the cytoplasm as well as the nucleus. In the cytoplasm, ECT2 is reported to bind to PKCi-Par6a and activate the Rac1 and MAPK pathway. Therefore, cytoplasmic ECT2 is thought to be associated with tumor growth and invasion. In the present study, we examined the clinicopathological implication of cytoplasmic ECT2 in terms of patient outcome, and also the biological significance of cytoplasmic ECT2 using lung adenocarcinoma cell lines.
    
    Methods:
    To examine the clinicopathological implication of cytoplasmic ECT2, 66 cases of various types of lung adenocarcinoma were examined using immunohistochemistry (IHC). Nine lung adenocarcinoma cell lines – A549, Calu-3, HCC827, LC-2/ad, NCI-H23, NCI-H1650, NCI-H1975, PC-9 and RERF-LC-KJ – were genetically examined for ECT2 amplification using FISH and for intracellular localization of ECT2 by Western blotting.
    
    Results:
    Overexpression of ECT2 in the nucleus was closely associated with the MIB-1 index (r=0.76) and was a strong prognostic factor of lung adenocarcinoma (OS; P=0.0096, DFS; P=0.019). On the other hand, cytoplasmic ECT2 was also associated with patient outcome (OS; P=0.02, DFS; P=0.023). Two of the nine lung adenocarcinoma cell lines, Calu-3 and A549, expressed ECT2 in the cytoplasm as well as the nucleus.Figure 1
    
    
    
    Conclusion:
    Cytoplasmic ECT2 is a prognostic factor of lung adenocarcinoma, and some lung adenocarcinoma cell lines show localization of ECT2 in the cytoplasm as well as the nucleus.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.